Osteochondral tissue coculture: An in vitro and in silico approach

Osteochondral tissue coculture: An in vitro and in silico approach
复制标题

DOI:
10.1002/bit.27127
复制
发表时间:
2019-07
影响因子:
3.8
通讯作者:
Ruikang Xue;Benedict Chung;M. Tamaddon;J. Carr;Chaozong Liu;S. Cartmell
Ruikang Xue;Benedict Chung;M. Tamaddon;J. Carr;Chaozong Liu;S. Cartmell
中科院分区:
工程技术2区
文献类型:
--
作者:
Ruikang Xue;Benedict Chung;M. Tamaddon;J. Carr;Chaozong Liu;S. Cartmell

文献摘要

相似文献

骨软骨组织工程旨在再生功能组织-模拟损伤软骨及其软骨下骨的生理特性。考虑到骨和软骨在结构和生化方面的不同,通常采用双层支架和生物反应器。我们提出了一种骨软骨培养系统,在双室灌注生物反应器中,在添加剂制造的双层支架上共培养ATDC5和MC3T3‐E1细胞。此外,基于制造支架的微计算机断层扫描图像和计算机辅助设计(CAD)建立了有限元模型(FEM);对两种有限元法的内部微环境进行了研究和比较。体外实验结果表明,共培养系统在细胞活力、增殖、分布和附着方面支持骨软骨组织生长。计算机实验结果表明,CAD和实际制造的支架在流速、生物反应器中分化介质的混合以及细胞经历的流体诱导剪切应力方面存在显著差异。该系统被证明具有骨软骨组织工程所需的微环境,并且可以作为一种廉价的工具来测试新开发的骨软骨缺陷药物产品。
Osteochondral tissue engineering aims to regenerate functional tissue‐mimicking physiological properties of injured cartilage and its subchondral bone. Given the distinct structural and biochemical difference between bone and cartilage, bilayered scaffolds, and bioreactors are commonly employed. We present an osteochondral culture system which cocultured ATDC5 and MC3T3‐E1 cells on an additive manufactured bilayered scaffold in a dual‐chamber perfusion bioreactor. Also, finite element models (FEM) based on the microcomputed tomography image of the manufactured scaffold as well as on the computer‐aided design (CAD) were constructed; the microenvironment inside the two FEM was studied and compared. In vitro results showed that the coculture system supported osteochondral tissue growth in terms of cell viability, proliferation, distribution, and attachment. In silico results showed that the CAD and the actual manufactured scaffold had significant differences in the flow velocity, differentiation media mixing in the bioreactor and fluid‐induced shear stress experienced by the cells. This system was shown to have the desired microenvironment for osteochondral tissue engineering and it can potentially be used as an inexpensive tool for testing newly developed pharmaceutical products for osteochondral defects.